Neogi Tuhina, Li Shanshan, Peloquin Christine, Misra Devyani, Zhang Yuqing
Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, Massachusetts, USA.
Ann Rheum Dis. 2018 Jan;77(1):92-97. doi: 10.1136/annrheumdis-2017-211811. Epub 2017 Oct 7.
Bone remodelling as a therapeutic target in knee osteoarthritis (OA) has gained much interest, but the effects of antiresorptive agents on knee OA have been conflicting, with no studies to date examining the effects of bisphosphonate use on the clinically relevant endpoint of knee replacement (KR) surgery.
We used data from The Health Improvement Network (THIN), a general practitioner electronic medical records representative of the general UK population. We identified older women who had initiated bisphosphonate use after their incident knee OA diagnosis. Each bisphosphonate initiator was propensity score-matched with a non-initiator within each 1-year cohort accrual block. The effect of bisphosphonates on the risk of KR was assessed using Cox proportional hazard regression. Sensitivity analyses to address residual confounding were also conducted.
We identified 2006 bisphosphonate initiators, who were matched to 2006 non-initiators(mean age 76, mean body mass index 27), with mean follow-up time of 3 years. The crude incidence rate of KR was 22.0 per 1000 person-years among the initiators, and 29.1 among the non-initiators. Bisphosphonate initiators had 26% lower risk of KR than non-initiators(HR 0.74, 95% CI 0.59 to 0.93); these results were similar when additionally adjusted for potential confounders in the propensity score (HR 0.76, 95% CI 0.60 to 0.95). Results of sensitivity analyses supported this protective effect.
In this population-based cohort of older women with incident knee OA, those with incident bisphosphonate users had lower risk of KR than non-users of bisphosphonates, suggesting a potential beneficial effect of bisphosphonates on knee OA.
骨重塑作为膝关节骨关节炎(OA)的治疗靶点已引起广泛关注,但抗吸收药物对膝关节OA的影响一直存在争议,迄今为止尚无研究探讨双膦酸盐使用对膝关节置换(KR)手术这一临床相关终点的影响。
我们使用了来自健康改善网络(THIN)的数据,这是一个代表英国普通人群的全科医生电子病历数据库。我们确定了在初次诊断膝关节OA后开始使用双膦酸盐的老年女性。在每个1年队列累积组中,将每位双膦酸盐使用者与一名非使用者进行倾向评分匹配。使用Cox比例风险回归评估双膦酸盐对KR风险的影响。还进行了敏感性分析以解决残余混杂问题。
我们确定了2006名双膦酸盐使用者,他们与2006名非使用者(平均年龄76岁,平均体重指数27)匹配,平均随访时间为3年。双膦酸盐使用者中KR的粗发病率为每1000人年22.0例,非使用者中为29.1例。双膦酸盐使用者发生KR的风险比非使用者低26%(风险比0.74,95%置信区间0.59至0.93);在倾向评分中额外调整潜在混杂因素后,这些结果相似(风险比0.76,95%置信区间0.60至0.95)。敏感性分析结果支持这种保护作用。
在这个基于人群的初次发生膝关节OA的老年女性队列中,初次使用双膦酸盐的患者发生KR的风险低于未使用双膦酸盐的患者,提示双膦酸盐对膝关节OA可能有有益作用。